Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 25.1 molecularly driven trial of rucaparib, bevacizumab, carboplatin, and paclitaxel in advanced ovarian cancer
2024-516632-99-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib, bevacizumab, carboplatin, paclitaxel in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Policlinico Gemelli. Planned start Mar 2021; status: authorised.
02
Drugs
rucaparibbevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-516632-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516632-99-00.